The fight against cancer has a new weapon. Eric Lefkofsky has partnered with the world famous Mayo Clinic to help in the battle against various forms of cancer, including lung cancer, melanoma, bladder cancer, breast cancer and lymphoma. The science behind the role of Lefkofsky company plays involves the ability to study cancer at the genetic level.Lefkofsky hopes this will not be the only partnership he creates. Tempus has already formed partnerships with other health care organizations that include Rush University Medical Center and Northwestern University’s Robert H. Lurie Comprehensive Cancer Center.
Lefkofsky educational background, that includes the University of Michigan and a JD from University of Michigan Law School, along with current duties as an adjunct professor at the University of Chicago, give him an insight into the role of research at the university level.Lefkofsky hopes that the role this new partnership has will be a help to oncologists, who will be able to access a vast database and in doing save valuable time and hugely affect survival rates.
The new partnership has already been given a boost by the injection of $80 million of new business investment.The end game to the partnership will the formation of a database so thorough that decisions on cancer treatments can be tailored to the patient and time can be saved by not using treatments that would not be effective. The partnership will have the ability to process the data of 50,000 patients a year. The database will help creative an holistic strategy that will help with all aspects of the treatment process.